The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome

  • Lee, Ji Hyun (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Ahn, Sung Gyun (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Park, Bonil (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Park, Sang Wook (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Kang, Yong Seok (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Lee, Jun-Won (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Youn, Young Jin (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Ahn, Min-Soo (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Kim, Jang-Young (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Yoo, Byung-Su (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Lee, Seung-Hwan (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Yoon, Junghan (Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine)
  • Received : 2014.07.28
  • Accepted : 2014.11.03
  • Published : 2015.09.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Newer $P2Y_{12}$ inhibitors, such as prasugrel and ticagrelor, have greater antiplatelet efficacy but may increase the risk of bleeding. In this study, we compared the pharmacodynamic efficacy of prasugrel and ticagrelor in East Asian patients with acute coronary syndrome (ACS). Methods: We selected 83 ACS patients undergoing percutaneous coronary intervention who were discharged with 90 mg ticagrelor twice daily (n = 24), 10 mg prasugrel daily (n = 39) or 5 mg prasugrel daily (n = 20). After 2 to 4 weeks, on-treatment platelet reactivity (OPR) was assessed in terms of $P2Y_{12}$ reaction units (PRUs) using the VerifyNow $P2Y_{12}$ assay (Accumetrics). We compared East Asian ($85<PRU{\leq}275$) and Caucasian ($85<PRU{\leq}208$) criteria for assessing the therapeutic window of OPR. Results: OPR was lowest in the ticagrelor group, followed by the 10 mg prasugrel and 5 mg prasugrel groups ($49.1{\pm}29.9$ vs. $83.7{\pm}57.1$ vs. $168.5{\pm}60.8$, respectively; p < 0.001). The 5 mg prasugrel group had the highest proportion of patients with OPR values within the therapeutic window, followed by the 10 mg prasugrel and ticagrelor groups (90.0% vs. 46.2% vs. 12.5%, respectively; p < 0.001 for East Asian criteria; 60.0% vs. 43.6% vs. 12.5%, respectively; p < 0.001 for Caucasian criteria). Conclusions: Short-term administration of 5 mg prasugrel facilitated maintenance within the therapeutic window of OPR compared with the 10 mg prasugrel and ticagrelor groups. Thus, 5 mg prasugrel daily may be the optimal antiplatelet regimen for stabilized East Asian ACS patients.

Keywords

References

  1. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
  2. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-2585. https://doi.org/10.1161/CIRCULATIONAHA.109.912550
  3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. https://doi.org/10.1056/NEJMoa0706482
  4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057. https://doi.org/10.1056/NEJMoa0904327
  5. Small DS, Kothare P, Yuen E, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol 2010;66:127-135. https://doi.org/10.1007/s00228-009-0737-1
  6. Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig 2012;32:87-97. https://doi.org/10.2165/11595930-000000000-00000
  7. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008;51:2028-2033. https://doi.org/10.1016/j.jacc.2008.04.002
  8. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-2944. https://doi.org/10.1093/eurheartj/ehr422
  9. Sibbing D, Steinhubl SR, Schulz S, Schomig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010;56:317-318. https://doi.org/10.1016/j.jacc.2010.03.048
  10. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382:614-623. https://doi.org/10.1016/S0140-6736(13)61170-8
  11. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011;57:2474-2483. https://doi.org/10.1016/j.jacc.2010.12.047
  12. Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273. https://doi.org/10.1016/j.jacc.2013.07.101
  13. Ahn SG, Lee SH, Yoon JH, et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012;5:259-267. https://doi.org/10.1016/j.jcin.2011.12.009
  14. Park DW, Ahn JM, Song HG, et al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2013;165:34-42.e1. https://doi.org/10.1016/j.ahj.2012.10.013
  15. Ko YG, Suh JW, Kim BH, et al. Comparison of 2 point-ofcare platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383-390. https://doi.org/10.1016/j.ahj.2010.10.036
  16. Park KW, Jeon KH, Kang SH, et al. Clinical outcomes of high on-treatment platelet reactivity in Koreans receiving elective percutaneous coronary intervention (from results of the CROSS VERIFY study). Am J Cardiol 2011;108:1556-1563. https://doi.org/10.1016/j.amjcard.2011.07.012
  17. Jin HY, Yang TH, Kim DI, et al. High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol 2013;167:1877-1881. https://doi.org/10.1016/j.ijcard.2012.04.154
  18. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009;119:2625-2632. https://doi.org/10.1161/CIRCULATIONAHA.107.696732
  19. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-242. https://doi.org/10.1161/CIRCULATIONAHA.108.812636
  20. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-1223. https://doi.org/10.1001/jama.2011.1332
  21. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-1105. https://doi.org/10.1001/jama.2011.290
  22. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054. https://doi.org/10.1093/eurheartj/ehr236
  23. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619. https://doi.org/10.1093/eurheartj/ehs215
  24. Ge J, Zhu J, Hong BK, et al. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Curr Med Res Opin 2010;26:2077-2085. https://doi.org/10.1185/03007995.2010.502048
  25. Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circ J 2014;78:1684-1692. https://doi.org/10.1253/circj.CJ-13-1482
  26. Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013;309:1022-1029. https://doi.org/10.1001/jama.2013.1556
  27. Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE- Korea registries. J Am Coll Cardiol 2013;61:536-544. https://doi.org/10.1016/j.jacc.2012.11.015
  28. Jeong YH. "East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome. Curr Cardiol Rep 2014;16:485. https://doi.org/10.1007/s11886-014-0485-4
  29. Park DW, Lee SW, Yun SC, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. J Am Coll Cardiol 2011;58:2630-2639. https://doi.org/10.1016/j.jacc.2011.08.057
  30. Yang TH, Kim DI, Kim DK, et al. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med 2011;26:145-152. https://doi.org/10.3904/kjim.2011.26.2.145
  31. Kelley-Hedgepeth A, Lloyd-Jones DM, Colvin A, et al. Ethnic differences in C-reactive protein concentrations. Clin Chem 2008;54:1027-1037. https://doi.org/10.1373/clinchem.2007.098996
  32. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009;123 Suppl 4:S11-S17. https://doi.org/10.1016/S0049-3848(09)70136-7
  33. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007;50:309-315. https://doi.org/10.1016/j.jacc.2007.01.098
  34. Mak KH, Bhatt DL, Shao M, et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009;157:658-665. https://doi.org/10.1016/j.ahj.2008.08.031
  35. Jeong YH, Bliden KP, Tantry US, Gurbel PA. Do East Asians have different hypercoagulable states compared with Western population? Am Heart J 2011;162:e19-e20. https://doi.org/10.1016/j.ahj.2011.05.001
  36. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109. https://doi.org/10.1056/NEJMoa1209979

Cited by

  1. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction vol.27, pp.4, 2015, https://doi.org/10.3109/09537104.2015.1095875
  2. East Asian perspective on the interaction between proton pump inhibitors and clopidogrel vol.32, pp.6, 2015, https://doi.org/10.1111/jgh.13712
  3. Higher Risk of Bleeding in Asians Presenting With ST Elevation Myocardial Infarction (STEMI) vol.69, pp.6, 2018, https://doi.org/10.1177/0003319717731961
  4. Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary inter vol.98, pp.11, 2015, https://doi.org/10.1097/md.0000000000014833
  5. Platelet inhibition to target reperfusion injury trial: Rationale and study design vol.42, pp.1, 2015, https://doi.org/10.1002/clc.23110
  6. Platelet activity with hemoglobin level in patients with hemodialysis : Prospective study vol.99, pp.10, 2015, https://doi.org/10.1097/md.0000000000019336
  7. The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel vol.36, pp.2, 2021, https://doi.org/10.3904/kjim.2019.293
  8. Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial vol.10, pp.12, 2015, https://doi.org/10.3390/jcm10122699